Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous anti-CD22 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Dongguan Taixin Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous anti-CD22 CAR-T cells are a chimeric antigen receptor (CAR) T-cell therapy consisting of autologous T lymphocytes genetically engineered to target CD22, a cell surface glycoprotein expressed on B-lineage cells. This cell therapy is being evaluated for the treatment of B-cell malignancies, including relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Dongguan Taixin Hospital has investigated these autologous anti-CD22 CAR-T cells in a Phase I clinical trial in China for patients with relapsed or refractory B-ALL.
- Other names
- autologous anti-CD22 CAR T cellsautologous anti-CD22 chimeric antigen receptor T cells
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on autologous anti-CD22 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous anti-CD22 CAR-T cells.